Continuous subcutaneous insulin infusion for the treatment of diabetes (review)

Similar documents
Personal statement on Continuous Subcutaneous Insulin Infusion Professor John Pickup

Audit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)

People living with type 1 diabetes face a. Barriers to improving glycaemic control in CSII. Joan Everett, Anita Bowes, David Kerr

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

DIABETES STRUCTURED EDUCATION IN WORCESTERSHIRE Information for Healthcare Professionals May 2011

Placename CCG. Policies for the Commissioning of Healthcare

Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus

Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancertreatment

DAFNE Audit Auditor Questionnaire

What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?

What needs to happen in England

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Clinical Snapshot: Making sense of Autonomic Neuropathy. M S Kamaruddin Consultant Physician South Tees NHS Foundation Trust

NHS Leeds CCG. Policy for the Funding of Flash Glucose Monitoring (FlashGM) in Paediatrics and Adults

COPYRIGHTED MATERIAL. Chapter 1 An Introduction to Insulin Pump Therapy WHAT IS INSULIN PUMP THERAPY?

Chapter 11 summary definitief ineke brands.indd :57:59

Injectable Therapies in Diabetes

Placename CCG. Policies for the Commissioning of Healthcare

Information for all patients taking insulin who are admitted to hospital on day of surgery

Description of the technology

Insulin pumps. Norman Waugh Warwick Medical School.

Re: Inhaled insulin for the treatment of type 1 and type 2 diabetes comments on the Assessment Report for the above appraisal

Insulin pumps (CSII): Using Modern technology to communicate with families of children with type 1 diabetes

1. What s the point of a network the case for research? 2. How to use CSII effectively

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system

Policy for the Provision of Continuous Glucose Monitoring and Flash Glucose Monitoring to patients with Diabetes Mellitus

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

Policy for Continuous Glucose Monitoring for Type 1 Diabetic Paediatric Patients (<18 years of age)

National Diabetes Insulin Pump Audit, England and Wales

Advances in Diabetes Care Technologies

Minutes of Educator Network 3 Meeting 25 April 2013 Cripps Post Graduate Centre, Northampton General Hospital, Area J, NN1 5BD

Type 1 Diabetes: diagnosis and management. Stakeholder workshop

CLINICAL UTILITY OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN PATIENTS WITH TYPE 1 DIABETES: A MACEDONIAN REPORT

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children

National Diabetes Inpatient Audit (NaDIA) 2016

Case Study: Competitive exercise

Paediatric Diabetes Service Operational Policy

Worcestershire Dementia Strategy

In keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:

Insulin Optimisation Workshop. Theingi Aung & Claire Rowell

Injectable Therapies in Diabetes

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

Advances in Diabetes Care Technologies

Injectable Therapies in Diabetes

This certificate-level program is non-sponsored.

Diabetes, Ketone testing in Type 1 Diabetes

Improving Diabetes Care The role of the integrated diabetes network. Ian Gallen Royal Berkshire Hospital

Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES

Diabetes in England NHS Medical Directorate. Dr Rowan Hillson MBE National Clinical Director for Diabetes

Insulin pump evaluation

Diabetes Subcommittee of PTAC meeting held 3 March (minutes for web publishing)

Insulin Safety. Tracey Roe DSN SSOT partnership trust

hypoglycaemia unawareness keystone 18 July 2014

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

BEST 4 Diabetes. Optimisation of insulin module

Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes

Hypoglycaemia in the community

Managing Problematic Hypoglycaemia Pratik Choudary


Approach to the Young child & Parent with Child with DM Best Structure for Continued Care

Diabetes is a lifelong, chronic. Survey on the quality of diabetes care in prison settings across the UK. Keith Booles

Fine-tuning of The Dose of Insulin Pump

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

Self-assessment checklist

BEST 4 Diabetes. Optimisation of insulin module

Guidance for Insulin Pump (CSII) use in hospital. Information for staff Diabetic Care

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Understanding patient experience of diabetes in London: Identifying what s needed to support those living and coping with diabetes

CAMHS. Your guide to Child and Adolescent Mental Health Services

Guideline for Children with Type 1 or Type 2 Diabetes on Insulin Requiring Surgery or Sedation

Continuous Subcutaneous Insulin Infusion (CSII) pump therapy

CGM Therapy Expert Program

Priorities Advisory Committee

Type 1 Diabetes and Eating Disorders

Glycaemic control in a type 1 diabetes clinic for younger adults

DESANG MEET INPUT. diabetes magazine. The group helping diabetics find funding for pumps and CGM

Initiation of insulin adjustment for carbohydrate at onset of diabetes in children using a home-based education programme with a bolus calculator

The National service framework (NSF) for diabetes

Pre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013

THE SHEFFIELD AREA PRESCRIBING GROUP. Position Statement for Prescribing of Freestyle Libre In Type 1 Diabetes. Date: March 2018.

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

DISCOVER THE POWER OF CONNECTION MINIMED 640G

Increasing prevalence chronic disease. Increasing demands on over-stretched NHS resources

DIABETES Self Directed Test (12 Hours) Name: Ward/Practice Area: Mailing Address:

University Hospitals of Leicester NHS Trust. Carbohydrates. A guide to carbohydrate containing foods for people with diabetes

Personal Report on the place of inhaled insulin in the NHS. Submitted to the Appraisal Committee of the HTA. 3 rd March 2006

Diabetes group education classes

Insulin Titration- Group Education

Interpretation and management of fasting hyperglycaemia in adults with Type 1 diabetes using MDI insulin regimen

Diabetes Update and DKA Queensland Paediatric Society of QLD Dr. Jason Yates Paediatric Endocrinologist

The REPOSE (Relative Effectiveness of Pumps over MDI and Structured Education) Trial

Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico

Dementia Strategy MICB4336

Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins

Transcription:

National Institute for Health and Clinical Excellence Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Royal College of Nursing Introduction With a membership of over 395,000 registered nurses, midwives, health visitors, nursing students, health care assistants and nurse cadets, the Royal College of Nursing (RCN) is the voice of nursing across the UK and the largest professional union of nursing staff in the world. RCN members work in a variety of hospital and community settings in the NHS and the independent sector. The RCN promotes patient and nursing interests on a wide range of issues by working closely with the Government, the UK parliaments and other national and European political institutions, trade unions, professional bodies and voluntary organisations. Response to the Assessment Report on the health technology appraisal of Continuous subcutaneous insulin infusion for the treatment of diabetes (review) The Royal College of Nursing welcomes the opportunity to review this document. In general we agree with the interpretation of the evidence. The Health Technology Assessment Report appears to be a comprehensive reflection of the evidence base. In addition to the evidence considered, the systematic review by Winckley et al (2006) in the British Medical Journal (BMJ) may be worth referring to with regard to the findings which found psycho-educational interventions were significantly more effective in children than adults and therefore may indicate a different approach to structured education for pump therapy in children. We would like to comment on how the clinical results should be interpreted in the context of current clinical practice as detailed below: A clear selection criteria is emerging which is applicable nationally and should be used across board. There would probably be a need to develop main centres initially for CSII in order to gain sufficient level of experience. This, however, would require funding to support it.

With respect to the incidence of diabetes of 26.5 per 100,000 as at 2003/04 in comparison to 17 per 100,000 in 1985-1990, in our view, this increase in incidence of diabetes coupled with the increase in intensity of management supports the need for a review of workforce requirements. The potential for 1% reduction in HbA1c (43/46 studies showed a reduction) and 0.5% from psycho-educational interventions (Winckley et al 06 systematic review) means children in the UK will have a much better chance of achieving the HbA1c target of 7.5%. If pump therapy use is expanded, considerable educational needs for both the patient and Health care professional will need to be addressed. It is our understanding that Leeds offers the only pump course which specifically addresses the needs of Children and young people. There would therefore, be a need to encourage and raise awareness of the importance of structured education pre-pump use, especially basal dose adjustment and SMBG. The literature found no evidence of increased risk of DKA in CSII but Hanas data shows this may be an emerging finding. This may indicate a learning need which goes beyond merely providing information and may require more active involvement and problem solving and skilful facilitation from an experienced team to really aid understanding of the speed and severity of which DKA can occur in pumps compared to basal bolus regime using long acting insulin. There is a need to address the difficulty of lunch time injection at school so that more children are able to use a basal bolus regime as many were on BD insulin regimes to avoid difficulties with injecting at school which is not acceptable. The need to address health care professionals negative attitude and perceptions of CSII is fundamental to maintaining the confidence of children and families and enabling them to make informed choices regarding treatment options. Doyle (2004) CSII better than analogue in children. Clinical experience indicates the ability to finely tune the basal rate in the middle of the night and early morning is more effective than analogue insulins. Adjusting and setting basal rates, choice of food bolus available to more accurately match type and amount of food and the need for more immediate action to prevent DKA requires more support and education and will not be covered in a structured education programme such as DAFNE. Basal rate at 6-9am is often double the amount between 24-6am due to dawn phenomenon. The impact which hypos have on IQ (Gold and Frier 95) with deficits found mostly in children diagnosed under 5yrs supports clinical experience that children under 5 years should be offered insulin pump therapy from diagnosis. We would suggest that a child on less than 20u/day should be considered for pumps.

Fear of hypos affects the family not just child (Clarke 98) and is the most likely reason for not achieving recommended HbA1c targets therefore psycho-educational interventions which address this should be available as part of routine care. The evidence for using pumps in children is growing particularly in younger children. There are difficulties managing injections in school (so pumps are considered to be comparatively easier). Also IQ deficits, chronic fear of hypos, better moods being a universal comment all these issues contribute to a compelling case for pumps from diagnosis. Young children have a lot to gain from early initiation of CSII and should be offered at diagnosis. Metabolic memory means early aggressive treatment should be mandatory (Ihnat 2007-09- 09). We would agree with the view that 35% of parents said change did not go as well as anticipated this also fits with clinical experience. We would suggest that families should be informed of this prior to pump start. In some areas, 10 days to 3/12 was identified as the time required to feel comfortable with CSII. QoL Barnard et al (2007) - currently no QoL gains from CSII in current evidence base but this may indicate a lack of evidence rather than evidence of no benefit. It was interesting to note the non health benefits - better moods in children treated with CSII was an almost universal comment. An important point made regarding use of the CORE model was that the main driver is HbA1c when in fact Quality of life gains from a reduced fear of hypo would have to be only relatively minor to make CSII cost effective. With regards to lack of tolerance to wearing a pump Saline pump starts are useful in children and young people as they benefit from a concrete experience of wearing the pump gaining insight into questions and responses from other people as well as managing their dressing and undressing etc. The indications for CSII in section 1.9 are an improvement. In the capital costs, the report lists 10 as the cost of meter. We understand that in one PCT meters are provided free to patients by the manufacturing companies either through the practice nurse or Diabetes Centre, so in that instance, there is no direct cost to the NHS. Patients who are being assessed for CSII will be under the care of a specialist diabetes team, therefore, have easy access to the meters. The cost to the NHS is from the test strip usage 4-8 tests per day. It is not clear if this practice is the same across board and should be taken into consideration in determining the cost of meters. Pump use have been reported to be successful. In one instance a patient was reported to have been on the pump for 3 years. The patient went on it because of recurrent DKA and prolonged admissions and the outcome since being on the pump has been reported to be very successful.

We are aware that in Worcestershire, they have a county wide pump panel with the PCT commissioner. They have a pathway that patients have to have undertaken which includes trying both Glargine o.d. and Detemir o.d or b.d. This has been reported to be very useful in helping to manage patients expectations and ensuring equity across the PCT. Conclusion CSII offers some benefits to some groups of patients, such as independence and better management of their condition. If pump therapy use is expanded, considerable educational needs for both the patient and Health care professional will need to be addressed. There would be a need to encourage and raise awareness of the importance of structured education pre-pump use, especially basal dose adjustment and SMBG.

References Winckley, K; Landau, S; Eisler, I & Ismail, K (2006). Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ July 2006, 333; 65